From patient trust to emerging evidence: Expert insights behind CBD and chronic pain management
Explore the latest research on CBD and pain relief, including highlights from patient insights, pre-clinical and clinical studies.
Cannabinoid actives
Together, advancing cannabinoid research and development with confidence
Realize the therapeutic potential of pharma CBD
We’re passionate about pioneering the next frontier in medicine – one that’s fueled by cannabinoid research and development. As an end-to-end partner to our customers, we offer a unique innovation platform powered by expert services. Designed to enhance the odds of therapeutic breakthroughs and streamline development pathways in the cannabinoid space, we’re enabling our customers to unlock new treatment possibilities and convenience for patients worldwide.
Discover our high-quality cannabidiol (CBD) pharma API portfolio, as well as the technical, clinical and regulatory expertise you need to navigate the ever-evolving cannabinoid market and expand into new geographies with confidence.
Stronger together
dsm-firmenich and Brains Bioceutical bring proven capabilities to simplify complex cannabinoid research and development; helping to reduce risks across the entire drug development pathway and support your path to success.
Looking for more information?
Download our brochure to discover new opportunities in tailor-made, patient-centric pharmaceuticals, driven by cannabinoid ingredients and expertise.
Discover CBtru® - a pioneering CBD drug intermediate enabling oral solid dosage forms with optimized bioavailability.
dsm-firmenich has developed CBtru®, a premium formulated CBD drug intermediate and patented solution, that presents several exciting opportunities for patients, healthcare professionals, and manufacturers of pharmaceutical products.
Whitepaper:
Cannabinoid-based
Drug Development
Due diligence considerations across the drug development journey
This whitepaper helps stakeholders across the drug development journey navigate the complexities of cannabinoid-based innovation more effectively. The paper addresses critical factors at every stage of drug discovery – from choosing the right cannabinoid API and increasing the odds of commercial success, all the way to fine-tuning patient experience, convenience and compliance.
Expert Panel - IBC Berlin, 2024
This panel, Future Scientific Horizons - Research and development in cannabinoid-based pharmaceuticals, was dedicated to discussing the future of cannabinoid-based pharmaceutical research and product development, and was led by Athanasia Kanli, Global Market Development Manager, dsm-firmenich.
Webinar
Best practice in cannabinoid-based R&D
Cannabinoids, such as cannabidiol, hold great therapeutic promise. However, currently available drug delivery formats, as well as ongoing R&D, face challenges with regard to API absorption and patient compliance. In this webinar we share learnings from an in-depth technology assessment for improving the bioavailability of CBD while enabling patient-friendly formats with high API loading.
Enter the cannabinoid actives market with confidence.
Step into the cannabinoid actives market with the support of industry-leading expertise and innovation. Partner with dsm-firmenich to develop high-quality, science-backed products that meet consumer demands and regulatory standards.
References
- Ożarowski, M., Karpiński, T. M., Zielińska, A., Souto, E. B., & Wielgus, K. (2021). Cannabidiol in Neurological and Neoplastic Diseases: Latest Developments on the Molecular Mechanism of Action. International journal of molecular sciences, 22(9), 4294. https://doi.org/10.3390/ijms22094294
- Argueta, D. A., Ventura, C. M., Kiven, S., Sagi, V., & Gupta, K. (2020). A Balanced Approach for Cannabidiol Use in Chronic Pain. Frontiers in pharmacology, 11, 561. https://doi.org/10.3389/fphar.2020.00561
- O'Brien K. (2022). Cannabidiol (CBD) in Cancer Management. Cancers, 14(4), 885. https://doi.org/10.3390/cancers14040885
Related articles
-
-
Supercharge your odds of scientific success with the dsm-firmenich CBD API sampling program
Learn more about dsm-firmenich’s CBD sampling program for early-stage cannabinoid research and development.
-
How is CBtru®, a novel drug product intermediate, pioneering patient-friendly CBD-based therapies? An expert view
In our Ask-the-Expert, we ask ‘Is our formulated CBtru® drug product intermediate the future of CBD innovation in the pharma market’?
Quick links
Customized blends of functional ingredients in one single, efficient premix.
Streamline your product development process and get to market faster.
From trade shows to conferences and other industry events, find out where you can meet us next.
Talking Nutrition, Health & Care
Explore new science, consumer insights, industry news and more in our latest articles.
Discover educational whitepapers, webinars, publications and technical information.
Request samples, place orders and view product documentation.